and men was 8.6 and 0.7 per 100,000 person-years, respectively. This rate was highest among black women (30.5), followed by Hispanic women (8.9), Asian women (7.2), and white women (5.3). The age-standardized prevalence in women per 100,000 persons was 458.1 in blacks, 177.9 in Hispanics, 149.7 in Asians, and 109.8 in whites. Capture-recapture modeling estimated 33 additional incident cases and 147 additional prevalent cases.
Conclusion. Comprehensive methods that include intensive case-finding provide more credible estimates of SLE in Hispanics and Asians, and confirm racial and ethnic disparities in SLE. The disease burden of SLE is highest in black women, followed by Hispanic women, Asian women, and white women.
Historical estimates of the incidence and prevalence of systemic lupus erythematosus (SLE) in the US have varied widely (1) . These differences stem from a variety of factors, including the definition of SLE used, completeness of case ascertainment, geographic area, and racial/ethnic composition of the study population. The heterogeneity of disease manifestations and the lack of an accurate, reliable diagnostic test result in substantial challenges and costs of conducting large-scale epidemiologic studies in SLE. In an effort to develop more authoritative estimates of the incidence and prevalence of SLE, the Centers for Disease Control and Prevention (CDC) initially provided funding for 2 population-based lupus surveillance registries: the Georgia Lupus Registry and the Michigan Lupus Epidemiology and Surveillance Program. These 2 registries, which were focused primarily on whites and blacks, have been successfully finished (2, 3) . To increase the reliability of SLE estimates in other racial/ethnic groups, the CDC funded 2 similar registries, one in California and the The views expressed herein are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Supported by the CDC (National Center for Chronic Disease Prevention and Health Promotion grant A114297). 1 Maria Dall'Era, MD: University of California, San Francisco; 2 Miriam G. Cisternas, MA: MGC Data Services, Carlsbad, California; other in New York, to focus on Hispanics and Asians, and a third registry with the Indian Health Service to focus on American Indians and Alaska Natives (4) .
In collaboration with the CDC and the California Department of Public Health, we conducted the California Lupus Surveillance Project (CLSP) to determine contemporary, population-based estimates of the incidence and prevalence of SLE in San Francisco County during the period 2007 through 2009 using multiple methods of case ascertainment. A secondary goal was to describe the clinical and serologic spectrum of incident SLE in the population. To the greatest extent possible, we aligned our methodology with that of the Georgia and Michigan registries (2, 3) to promote consistent data collection and optimal case ascertainment.
PATIENTS AND METHODS
The California Lupus Surveillance Project. The CLSP was conducted under the statutory authority of the California Department of Public Health (CDPH). Patients were not contacted for this study. A partnership between the CDPH and the University of California, San Francisco (UCSF), allowed medical records to be collected using the health surveillance exemption to the Health Insurance Portability and Accountability Act (HIPAA) privacy rules (45 CFR parts 160 and 164). The use of protected health information was essential in the conduct of this project in order to increase potential case-finding, perform unbiased case ascertainment, and prevent duplication of patients in the registry. The CDPH subcontracted with the UCSF to conduct this project. The State of California Institutional Review Board (IRB) granted a waiver for this public health surveillance activity, but the project was reviewed and approved by the UCSF IRB.
Source population/catchment criteria. The source population consisted of residents of San Francisco County, CA, during the period of January 1, 2007 through December 31, 2009. According to US Census estimates, the San Francisco County source population in 2007-2009 averaged 790,582 residents, 56% of whom identified themselves as white, 35% as Asian or Pacific Islander, 7% as black, and 1% as American Indian/Alaska Native (5). Of note, Hispanic ethnicity is considered a distinct concept from race and is therefore collected and reported separately from race; 15% of residents identified themselves as Hispanic ethnicity.
Case definitions. SLE is currently diagnosed in clinical practice by an expert clinician based on characteristic symptoms and signs in conjunction with supportive serologic and histologic data. For the purposes of this surveillance project in which clinical information was ascertained through review of medical records, we used various case definitions to classify a patient as having SLE. To maintain consistency with the Georgia and Michigan Lupus Registries (2,3), we report estimates using 2 case-finding definitions: the American College of Rheumatology (ACR) case definition and the combined case definition.
The ACR definition included patients who met $4 of the 11 ACR revised criteria for the classification of SLE as defined in 1982 and updated in 1997 (6, 7) . This is a standard case definition used for research. The combined definition was satisfied if a patient met any of the following 3 criteria. The patient satisfied the ACR case-finding definition as described above. The patient had documented SLE, as diagnosed by the treating rheumatologist, and met 3 of the 11 ACR classification criteria. This definition was chosen to allow for the possibility of missing data and an inability to confirm criteria in the available medical records for prevalent cases with longstanding disease. The patient had lupus-related kidney disease, as defined either by the presence of World Health Organization class II-VI lupus nephritis upon biopsy or by the presence in the medical record of a diagnosis of SLE (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 710.0) along with either dialysis or renal transplantation.
Case ascertainment. The 3 primary sources of potential SLE cases were as follows: 1) community rheumatology and nephrology clinics (office-based practices), 2) community hospitals (nonacademic hospitals), and 3) integrated health care systems (integrated hospitals and clinics) within the catchment area, including the UCSF, Kaiser Permanente of Northern California, and the San Francisco Veterans Administration Medical Center ( Figure 1 ).
We queried these sources over the period 2000-2009 using ICD-9-CM diagnostic codes 710.0 (SLE), 695.4 (discoid lupus), 710.8 (other specified connective tissue disease [CTD]), and 710.9 (unspecified CTD). A secondary source was a commercial laboratory, which we queried for the following serologic tests: antinuclear antibodies, anti-double-stranded DNA antibodies, anti-Sm antibodies, antiphospholipid antibodies, and low complement levels. Another secondary source was the California Office of Statewide Health Planning and Development (OSHPD) hospital discharge database, which we queried for discharges using the ICD-9-CM diagnostic codes 710.0 (SLE), 695.4 (discoid lupus), 710.8 (other specified CTD), and 710.9 (unspecified CTD). We added patients identified from the OSHPD query to the roster of the appropriate primary source hospitals and integrated health care systems.
After compiling a list of potential SLE patients from all sources using the queries described above, we determined catchment criteria for each patient (proof of residence in San Francisco County during the period 2007-2009). The primary methods for verifying catchment criteria were via the LexisNexis online database service, hospital billing databases, and clinic medical records. We then abstracted medical records for each of the potential SLE patients who met catchment criteria to identify those whose medical record had a physician diagnosis of SLE, possible SLE, undifferentiated/ unspecified CTD, or a related connective tissue disorder, such as mixed CTD.
Data collection. Four trained field staff abstracted medical charts for each potential SLE patient who met the catchment criteria. Training of the staff included lectures by physicians, extensive reading about SLE clinical manifestations and terminology, and practice abstractions of patient charts that were then reviewed in detail by the principal investigator (MD). The field abstractors accessed all available medical records (paper charts and electronic medical records) at each source location, collecting more than 200 data elements. Laboratory records were reviewed for the presence or absence of antibodies and for the presence or absence of low complement levels.
The abstractors recorded whether the source was a community clinic, community hospital, or integrated health care system as described above. As questions arose about the information in the medical records, the abstractors contacted the principal investigator in real time to obtain clarifications. Demographic information was obtained from the medical record. For quality control, a second field abstractor and the principal investigator reviewed 5 of every 100 charts for each abstractor, and data entry errors identified by discordant responses between abstractors were examined and corrected. Overall, we calculated 98% concordance between abstractors for the required data elements (those used to define the ACR criteria) and 93% concordance for all other data elements.
Statistical analysis. We derived all denominators for incidence and prevalence using . We calculated the annual period prevalence (cases per 100,000 persons) for each year separately, dividing the number of SLE cases diagnosed before or during that year in persons residing in San Francisco County during the year by the San Francisco County population of that year. We then averaged the 3 annual prevalence estimates to yield the average annual prevalence for 2007-2009. Our next step was to calculate exact 95% confidence intervals (95% CIs) (8) for the incidence rate and average annual prevalence.
We calculated age-standardized incidence and prevalence using the direct method, based on the 2000 US projected population (distribution no. 2) (9). In addition, we computed age-specific estimates using 10-year age groups, as well as sexspecific estimates. The intercensal database of the Census Bureau codes race and Hispanic ethnicity using 2 variables. One collapses all persons into 4 mutually exclusive categories defined by bridged race, without accounting for Hispanic ethnicity: black, white, Asian/Pacific Islander, and American Indian/Alaska Native (10) . The other codes Hispanic ethnicity as a separate construct.
Similar to the Georgia registry (2), we used capturerecapture methods to estimate underascertainment of cases. Specifically, we developed log-linear models that estimated the number of missing cases predicted by the overlap among the 3 primary sources (community rheumatology and nephrology clinics, community hospitals, and integrated health care systems). We evaluated the results of all log-linear models possible for a 3-source capture-recapture analysis and then chose the best-fitting model based on chi-square goodness-of-fit criteria (11) . Using the estimated number of undercounted cases from the best-fitting model, we calculated the capturerecapture revised incidence and prevalence estimates for the ACR definition. P values less than 0.05 were considered significant.
We compared differences between estimates by case definition using the 95% CIs of the age-adjusted rates. Nonoverlapping 95% CIs were considered to be significantly different.
RESULTS
Study population. As shown in Figure 1 , among 15,210 potential SLE patients identified from primary and secondary sources, 4,859 met the geographic and temporal catchment area criteria (residency in San Francisco County from 2007 through 2009). Abstraction was completed for 4,832 patients because 27 patients did not have any available medical records. Of the abstracted patients, 1,257 satisfied the catchment criteria and had a physician recorded diagnosis of SLE, possible SLE, undifferentiated/unspecified CTD, or a related connective tissue disorder such as mixed CTD in their medical record. Of these 1,257 cases, 121 incident and 796 prevalent cases met the ACR case definition while 137 incident and 909 prevalent cases met the combined case definition. All cases were confirmed using primary data sources, including those initially ascertained from state hospital discharge data. Commercial laboratory queries did not provide any additional cases.
Incidence rates according to the ACR case definition. The overall crude and age-standardized incidence rates were 5.1 (95% CI 4.3-6.1) and 4.6 (95% CI 3.8-5.5) per 100,000 person-years ( Table 1 ). The 121 incident cases consisted of 112 women and 9 men. Race for these cases was identified as black (n 5 27), white (n 5 43), Asian/Pacific Islander (n 5 39), and American Indian/Alaska native (n 5 1); no race was identified in 11 of them. Hispanic ethnicity was identified in 17 patients; 18 had no ethnicity identified. Among the Asian/Pacific Islander subgroup, the predominant race was Chinese (21 patients; 17 were identified as Chinese only, with the remaining 4 including another Asian/ Pacific Islander racial category) followed by Japanese (3 patients; 2 were exclusively Japanese), Filipino (2 patients; both of whom also had another Asian/Pacific Islander racial category), and 1 each of Korean, Vietnamese, Asian Indian, Samoan, and Hawaiian. The remaining 7 cases were classified as "other Asian," a category that included Burmese, Indonesian, and Asian not otherwise specified (data not shown). The age-standardized incidence rates were about 12 times higher among women than men: 8.6 versus 0.7 per 100,000 person-years. The age-standardized incidence rate was highest among black women (30.5 [95% CI 20.7-44.9]), followed by Hispanic women (8.9 [95% CI 5.3-14.8]), Asian women (7.2 [95% CI 5.1-10.2]), and finally, white women (5.3 [95% CI 3.8-7.5]). The age-standardized incidence rate among black women was ;6 times higher than among white women.
Among black women, the age-specific incidence rate peaked at 61.2 per 100,000 women in the 40-49-year-old age group. Among the other racial/ethnic groups, incidence rates were relatively constant across the age groups (Figure 2 ). There were too few incident cases in men (9 cases) to enable age stratification. The overall mean age at diagnosis was 43.9 years. The mean age at diagnosis stratified by bridged race/ethnicity was 40.1 years in blacks, 46.5 years in whites, 45.1 years in Asians, and 36.6 years in Hispanics. All 95% CIs for the race/ethnicity mean age estimates overlapped (data not shown).
Our capture-recapture modeling estimated 33 (95% CI 8-130) additional incident cases in the population. This yielded a capture-recapture inflated crude rate of 6.5 per 100,000 person-years.
Incidence rates according to the combined case definition. The combined definition yielded an additional 16 cases (15 from the 3 ACR criteria plus rheumatologist diagnosis criterion and a single case from the lupus-related kidney disease criterion) for a total of 137 incident cases ( Table 1 ). The overall crude and agestandardized incidence rates were 5.8 (95% CI 4.9-6.8) and 5.2 (95% 4.3-6.2) per 100,000 person-years. Sex and racial/ethnic disparities in the incident cases were similar to those observed in the ACR cases.
Prevalence according to the ACR case definition. The ACR definition yielded overall crude and agestandardized prevalence proportions of 96.0 (95% CI 89.4-103.1) and 84.8 (95% CI 78.6-91.5) per 100,000 persons ( Table 2 ). The 796 unique prevalent cases over the 3-year period consisted of 708 women and 88 men. We identified race for these cases as white (n 5 294), Asian/Pacific Islander (n 5 290), black (n 5 160), and American Indian/Alaskan native (n 5 4); race was not identified in 48 patients. Hispanic ethnicity was identified for 118 patients. Similar to the incident cases, the majority of the Asian/Pacific Islander subgroup was composed of Chinese (137 patients; 101 were identified as Chinese and no other race), followed by "other Asian" (56 patients), Filipino (42 patients; 26 were not identified with any other race), Vietnamese (18 patients; 12 had no other race identified), Japanese (10 patients; 8 were not identified with any other race), Korean (5 patients; 3 had no other race identified), Thai and Pakistani (4 patients each), Asian Indian and Samoan (3 patients each), other South Asian, Cambodian, and Pacific Islander not otherwise specified (2 patients each), and Hawaiian and Laotian (1 patient each) (data not shown).
Age-standardized prevalence was about 8 times higher among women than men: 155. 6 The 95% confidence intervals for the incidence rates overlapped within each age group, except for the groups ages 30-39 years and 40-49 years, where the rates for black women were statistically significantly higher than those in the other racial groups or Hispanics. The race categories are mutually exclusive. Hispanic ethnicity was recorded separately from race; therefore, persons of Hispanic ethnicity are also represented in the race categories (mostly white).
women. The age-standardized prevalence among black men was over 5 times higher than among white men.
The age-specific prevalence in the ACR-defined cases was statistically significantly higher in black women compared with women of other racial groups for ages 30-59 years, with whites and Asians for ages 69-79 years, and with whites only for ages 20-29 years. Among black women, age-specific prevalence began to increase at age 20 years and peaked at 954.5 per 100,000 in the group ages 40-49 years ( Figure 3 ). Among black men, age-specific prevalence peaked in the 50-69 year range. Age-specific prevalence was higher in black men as compared to the other racial/ethnic groups ( Figure 3 ). Among men, 95% CIs overlapped within each age group with the following exception: among those ages 50-59 years, the prevalence in black men was statistically significantly higher than in white men.
The overall mean age at diagnosis was 34.8 years. Age at diagnosis stratified by bridged race and ethnicity was as follows: 35.5 years in blacks, 34.4 years in whites, 34.6 years in Asians, and 33.9 years in Hispanics. Once again, the 95% CIs for these estimates overlapped (data not shown).
Our capture-recapture modeling estimated 147 (95% CI 93-225) additional prevalent cases in the population. This yielded a capture-recapture inflated average annual crude prevalence of 113.7 per 100,000 persons.
Prevalence according to the combined case definition. By including an additional 113 individuals (89 based on the 3 ACR criteria plus rheumatologist diagnosis criterion and 24 based on the lupus-related kidney disease criterion), the combined definition yielded a total of 909 unique individuals over the 3-year period (Figure 1 ), or 869 average annual prevalent cases ( Table 2 ). The overall crude and age-standardized prevalence proportions were 109.9 (95% CI 102.8-117.4) and 96.8 (95% 90.2-103.9) per 100,000 persons. Agestandardized prevalence proportions were 9 times higher among women than men: 179.4 versus 20.6 per 100,000 person-years. The age-standardized prevalence was highest among black women (498. immunologic, (80%), arthritis (57%), renal disorder (45%), pleuritis or pericarditis (41%), and malar rash (33%) ( Table 3) . Neurologic disorder was the least common manifestation (8%). Renal disorder occurred more commonly in the black (52%), Asian/Pacific Islander (51%), and Hispanic (47%) patients than in the white patients (40%). Discoid rash was highest among black patients (22%) compared to the other groups and was least common in the Asian (5%) and Hispanic (0%) patients. Similar trends in the frequencies of clinical manifestations across the racial and ethnic groups were observed among the prevalent cases meeting the ACR definition (data not shown).
DISCUSSION
The California Lupus Surveillance Project had the opportunity to extend previous CDC-funded epidemiologic work to include 2 additional racial/ethnic groups and to confirm striking racial and ethnic disparities in the incidence and prevalence of SLE. San Francisco County is diverse, with substantial numbers of Asian and Hispanic patients. We found that, in addition to African Americans, Asian/Pacific Islanders and Hispanics (of any race) have been disproportionately affected by SLE as compared to whites (regardless of Hispanic ethnicity). Of the Hispanic cases included in the analyses, the majority were identified as white or had no race identified, e.g., race categories for the ACR definition of prevalent cases of Hispanic ethnicity were white (69%), no race identified (25%), Asian/Pacific Islander (5%), and black (1%).
Hispanics currently comprise 16% and Asians 5% of the US population. By 2050, these numbers are expected to rise to 30% and 8%, respectively (12) . Thus, a reliable estimate of the burden of SLE in these growing populations is essential for health care planning. A major challenge to advancing knowledge in this area has been the paucity of large-scale, population-based surveillance studies with rigorously defined case definitions and case-finding procedures. Up until the recent completion of the Georgia and Michigan surveillance projects, most previous epidemiologic studies were limited by small geographic areas, homogenous populations, varying case definitions, and incomplete case ascertainment that relied on administrative codes or patient selfreported diagnosis. Such historical studies provided estimates ranging from 2.0 to 7.6 per 100,000 for the overall incidence and from 19 to 241 per 100,000 for the overall prevalence (13, 14) . The methods used in the CDC-funded registries, including the CLSP, have enabled us to determine more accurate and contemporary estimates of the incidence and prevalence of SLE in the US.
This study has several limitations. The first is the potential for incomplete case ascertainment. Although we used the HIPAA exemption for obtaining informed consent, each clinic and hospital had to voluntarily agree to participate in the CLSP. This issue led to the potential for incomplete case ascertainment. For example, 2 small community hospitals in San Francisco chose not to participate in the CLSP. Based on the proportion of discharges from these 2 hospitals to the total number Figure 3 . Average annual age-specific prevalence of systemic lupus erythematosus (SLE) among women and men living in San Francisco County, California, 2007-2009, categorized by race and Hispanic ethnicity. SLE was defined according to the American College of Rheumatology criteria. Among men, the 95% confidence intervals for prevalence overlapped within each age group, except for the group ages 50-59 years, where the prevalence in black men was statistically significantly higher than that in white men. The race categories are mutually exclusive. Hispanic ethnicity was recorded separately from race; therefore, persons of Hispanic ethnicity are also represented in the race categories (mostly white).
of discharges for San Francisco residents in 2007-2009 (16%) and the number of cases identified solely by community-based hospitals (9), we estimate that the lack of participation of these 2 hospitals resulted in potentially only 2 missed prevalent cases according to the ACR definition. Incomplete case ascertainment might also have occurred because we did not conduct field work in primary care clinics. Thus, it is possible that there were diagnosed cases of SLE in the community that never reached the attention of a specialist or had not been seen by a specialist for many years. Although capture-recapture analysis estimated an additional 33 incident cases and 147 prevalent cases, these estimates are imprecise, as indicated by the wide 95% CIs.
A second limitation is that data were collected from a review of the medical records rather than from direct patient interview and evaluation. The quality of medical record documentation of SLE manifestations varied widely. For longstanding, prevalent cases, it was sometimes difficult to retrieve the initial medical records that may have documented early manifestations of disease. Third, race and ethnicity were determined from the medical record and were not always well documented. This led to missing data for race and ethnicity as well as the potential for misclassification. Last, our denominator data were extracted from the US Census files, which provide population totals at the Federal Information Processing Standards level separately for race and ethnicity. Therefore, it was not possible for us to estimate the prevalence and incidence for mutually exclusive combined categories of these variables (e.g., non-Hispanic white).
One of the major strengths of the CLSP was the ability to conduct widespread case ascertainment by using a variety of sources, including university and community clinics, hospitals, regional laboratories, and state administrative databases. The abstractors comprehensively reviewed the patients' medical records, thereby minimizing underreporting bias in case ascertainment. The CDC funded this project with the specific intention of developing credible and complete estimates of the incidence and prevalence of lupus in Asians and Hispanics. Asians and Hispanics are generally smaller populations that we thought might access health care through alternative routes. To identify these patients, case-finding efforts were refined by working with physicians who were focused on those populations. For example, we partnered with a physician who cares for many of the Chinese patients in San Francisco at the Chinese Hospital. To access the Hispanic population in San Francisco, we performed extensive case-finding at San Francisco General Hospital and the associated community health network clinics. Our approach of partnering with the community and engaging culturally and linguistically concordant community members led to successful case ascertainment of these traditionally understudied populations. Had we not taken these extra steps, we would have missed SLE cases in the Asian and Hispanic populations.
SLE is a complex and heterogeneous disease for which there is no gold standard diagnostic test (15) . One of the challenges of large epidemiologic studies is the need to designate a diagnosis of SLE based on documentation in the medical record without the benefit of evaluating the patient in the clinical setting. For the purposes of the CLSP, we used case definitions identical to those utilized by other CDC-funded surveillance registries. In this way, consistent methodology across the registries was achieved. The primary case-finding definition used for the study was meeting $4 of the 11 revised classification criteria for SLE as defined by the ACR. Because case ascertainment relied on patients' medical records and sometimes not all medical records for a given patient were available, there was a potential for underdiagnosis of SLE if we had relied only on the ACR criteria definition. Therefore, we also used the combined case definition that was used by the Georgia Lupus Registry. The CLSP found high age-standardized mean annual incidence rates and prevalence proportions of 4.6 and 84.8 per 100,000, respectively, for the ACR definition and 5.2 and 96.8 per 100,000, respectively, for the combined definition. The data confirmed and quantified a higher burden of SLE in women and in racial and ethnic minorities. Using the ACR definition, the agestandardized female-to-male incidence ratio was 12:1, with an 8:1 prevalence ratio. The highest agestandardized mean annual incidence rates and prevalence proportions per 100,000 were found in black women (30.5 and 458.1, respectively), followed by Hispanic women (8.9 and 177.9, respectively), Asian women (7.2 and 149.7, respectively), and white women (5.3 and 109.8, respectively). Age-specific incidence rates and prevalence proportions were highest in black women, with peak incidence and prevalence in the group ages 40-59 years. The findings confirm previous studies that showed an increased burden of SLE among black women. For example, a population-based study in Allegheny County, PA, determined a 3-fold higher incidence rate among black women compared to white women during the years 1985-1990 (16) . The Georgia and Michigan registries also showed higher incidence and prevalence estimates among black women (2, 3) .
Interestingly, while the age-standardized incidence rate per 100,000 according to the ACR definition in CLSP was slightly lower (4.6) than those in the Georgia (5.6) and Michigan (5.5) registries, the CLSP agestandardized prevalence per 100,000 (84.8) was statistically significantly higher than that in either the Georgia (73.0) or Michigan (72.8) registries. While the reasons for the higher prevalence but lower incidence of SLE in CLSP are not clear, factors such as better access to health care and awareness of the disease in San Francisco compared to the locations of the other registries may be playing a role. Also, among black women, the age-standardized annual incidence rate and average annual prevalence per 100,000 (30.5 and 458.1) were .2 times higher in California compared to Georgia (13.4 and 196.2, respectively) and Michigan (12.8 and 186.3, respectively). Among white women, the agestandardized mean annual incidence rates were more similar among the 3 registries, although prevalence was still statistically significantly higher in the CLSP.
The reasons for the higher incidence and prevalence for black women in the CLSP compared with the other registries are not known, but may relate to several factors. With regard to the observed increased incidence, it is possible that the genetic ancestry of the black population in San Francisco is different from that in Georgia and Michigan, portending greater risk of disease. In addition, there may be environmental influences that increase the risk of SLE. Future studies will be required to address these important questions and further examine these possibilities.
There is a paucity of population-based studies estimating the incidence and prevalence of SLE among Hispanics and Asians in the US. Increased SLE disease activity and organ damage among US Hispanics versus non-Hispanic Caucasians have been previously noted by studies conducted within the LUpus in MInorities, NAture versus nurture (LUMINA) longitudinal cohort. LUMINA studies have also showed differing disease outcomes among various Hispanic subgroups, with worse outcomes occurring among Hispanics in Texas compared to Hispanics in Puerto Rico (17) (18) (19) . Because of reliance on medical record documentation of ethnicity in CLSP, we were unable to differentiate various Hispanic subgroups in the incidence and prevalence estimates. Fewer studies have examined differences in SLE frequency and severity in Asian patients. One recent study from the Monash Lupus Clinic in Melbourne, Australia, showed increased disease severity and serologic activity among Asian patients compared with white patients (20) . Thus, the CLSP contributes to an improved understanding of the burden of SLE among Asians and highlights the need for further work on disease phenotypes, outcomes, and drug responses which are likely to differ among patients from different racial and ethnic backgrounds.
In conclusion, the CLSP confirmed the increased burden of SLE in black, Asian, and Hispanic women compared to white women. Future studies will be necessary to broaden our understanding of the underlying etiologies for this disparity, including attempts to unravel the contributions of genetic and biologic factors versus social and environmental factors in order to improve patient outcomes. 2004 DALL'ERA ET AL
